Genzyme in India

Genzyme is committed to bringing transformative therapies for patients with rare and special unmet medical needs in India, providing hope where there was none before. More>

April 28, 2017: Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA Read More>

April 24, 2017: Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Read More>

April 5, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee Read More>

March 28, 2017: Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis Read More>


Genzyme India 15 year anniversary